 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| IAP0971 / SunHo BioPharma
New P1/2 trial: A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer (clinicaltrials.gov) - Feb 13, 2024
P1/2, N=236, Not yet recruiting, Sponsor: SUNHO?China?BioPharmaceutical CO., Ltd.
- || IAP0971 / SunHo BioPharma
New P1/2 trial, Metastases: A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Jan 25, 2024
P1/2, N=50, Recruiting, Sponsor: SUNHO?China?BioPharmaceutical CO., Ltd.
- ||| IAP0971 / SunHo BioPharma
Enrollment open, Metastases: A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Jul 20, 2023
P1/2, N=140, Recruiting, Sponsor: SUNHO?China?BioPharmaceutical CO., Ltd.
Not yet recruiting --> Recruiting
- IAP0971 / SunHo BioPharma
IAP0971, A novel PD1/IL15 immunocytokine that binds specifically to PD1 and fuses IL15/IL15R? complex (Section 25; Poster Board #28) - Mar 14, 2023 - Abstract #AACR2023AACR_4035;
P1/2
The indications of IAP0971 include lung cancer, cervical cancer, head and neck squamous cell carcinoma, liver cancer, lymphoma, and other malignant tumors. A Phase I/IIa clinical trial to evaluate the safety, tolerability and preliminary efficacy of IAP0971 in patients with locally advanced or metastatic malignant tumors is currently on-going (NCT05396391).
- | IAP0971 / SunHo BioPharma
Preclinical, Journal: Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex. (Pubmed Central) - Jan 24, 2023
P1/2
IAP0971 has demonstrated a favorable safety profile and potent anti-tumor activities in vivo. A Phase I/IIa clinical trial to evaluate the safety, tolerability and preliminary efficacy of IAP0971 in patients with advanced malignant tumors is on-going (NCT05396391).
- |||| IAP0971 / SunHo BioPharma
New P1/2 trial, Metastases: A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - May 30, 2022
P1/2, N=140, Not yet recruiting, Sponsor: SUNHO?China?BioPharmaceutical CO., Ltd.